Trial of MS1819, Yeast-based EPI Treatment, Opens 2 Sites in Poland

Trial of MS1819, Yeast-based EPI Treatment, Opens 2 Sites in Poland

284731

Trial of MS1819, Yeast-based EPI Treatment, Opens 2 Sites in Poland

Two new sites for the extension of a Phase 2b trial testing an immediate release capsule form of MS1819 in treating exocrine pancreatic insufficiency in cystic fibrosis (CF) have opened in Poland and are enrolling patients by invitation. Part of the OPTION 2 study (NCT04375878), these European sites join those already open in the U.S. in assessing the optimal dose of a yeast-based pancreatic enzyme replacement therapy (PERT) in eligible CF patients. Their addition is intended to minimize delays in enrollment…

You must be logged in to read/download the full post.